Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 studyMichael J. Overman, Thierry André, Ray McDermott et al.|The Lancet Oncology|2017Cited by 2.8k
Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancerJeanne Tie, Peter Gibbs, Yuxuan Wang et al.|Science Translational Medicine|2016Cited by 1.5k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal CancerScott Kopetz, Josep Tabernero, Axel Grothey et al.|New England Journal of Medicine|2019Cited by 1.5k
Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trialWilliam D. Tap, Andrew J. Wagner, Hans Gelderblom et al.|The Lancet|2019Cited by 472
Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma NetworkGeorge D. Demetri, Jean‐Yves Blay, Cristina R. Antonescu et al.|Annals of Oncology|2020Cited by 145